Biotechnology

Tuesday Dec 13, 2022 - 2:46 pm

InvestorNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Featured in ‘Stock2Me’ Podcast

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, was featured in the latest episode of the Stock2Me Podcast, an IBN solution to provide specialized content distribution via widespread syndication channels. BiondVax’s CEO Amir Reichman joined the latest episode to introduce the company and discuss its recent development efforts focused…

Tuesday Dec 13, 2022 - 10:02 am

InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Appoints Interim Chief Financial Officer, Changes Auditor

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, announced that Jonathan Tegge, a member of Brio Financial Group, will shoulder the role of interim CFO effective Dec. 12, 2022. The announcement accompanied the news that InMed has signed a service contract with Brio Financial Group to provide senior financial leadership and bookkeeping services. A financial…

Monday Dec 12, 2022 - 12:18 pm

InvestorNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Regains Compliance with Nasdaq Listing Rules

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today announced the receipt of formal notifications from the Nasdaq Stock Market that the company has regained Nasdaq compliance regarding minimum stockholders’ equity and minimum bid price. The company previously reported receipt of the respective non-compliance notifications on Sept. 30 and…

Friday Dec 09, 2022 - 11:20 am

InvestorNewsBreaks – MetAlert Inc. (MLRT) Featured in ‘Stocks to Watch’ by Markets Herald

MetAlert (OTC: MLRT) is a pioneer in location-sensitive health monitoring devices and wearable technology products for remote patient monitoring. The company was featured in a “Stocks to Watch” report published by Markets Herald, which offers current market trends and analysis across various sectors. “MetAlert (OTC: MLRT) took a significant step forward in the fourth quarter of 2022 by eliminating all toxic convertible notes from its…

Friday Dec 09, 2022 - 10:17 am

InvestorNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Featured in Investment Research Report

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, was featured in a recent report published by Zacks Small-Cap Research. In the report, Zacks valued BVXV at $57.00/ADS. The publication reads, “On November 30, 2022, BiondVax Pharmaceuticals Ltd. (BVXV) announced financial results for the third quarter of 2022 and provided…

Thursday Dec 08, 2022 - 11:33 am

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases Preliminary Results from Berubicin Trial

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has released data from its ongoing trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (“GBM”). The data was presented at the annual meeting for the Society for Neuro-Oncology. Those results indicate that enrolled patients have comparable demographics, including age,…

Wednesday Dec 07, 2022 - 2:36 pm

InvestorNewsBreaks – MetAlert Inc. (MLRT) Featured in Research Report

Ludlow Research has announced that it updated its research opinion on MetAlert (OTC: MLRT), a pioneer in location-sensitive health monitoring devices and wearable technology products for remote patient monitoring. The update is based on MetAlert’s elimination of toxic debt, as well as the launch of new medical device products for cognitive markets. “Toxic debt, or variable convertible notes, are a form of debt, which sometimes…

Wednesday Dec 07, 2022 - 11:19 am

InvestorNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Signs Agreement to Build Exclusive AIMIGo 12-Lead 3D VECG Device

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (“VECG”) platform for heart attack detection anytime, anywhere, is partnering with medical device manufacturing company Evolve Manufacturing Technologies to build its credit-card-sized AIMIGo(TM) 3D vector electrocardiogram (“VECG”) recording device; the device is designed to provide a 12-lead ECG readout to detect heart attacks remotely. According to the announcement, HeartBeam…

Wednesday Dec 07, 2022 - 11:13 am

InvestorNewsBreaks – India Globalization Capital Inc. (NYSE American: IGC) Applauds Milestone Development for Medical Cannabis Industry

India Globalization Capital (NYSE American: IGC) applauds the signing of the Medical Marijuana and Cannabidiol Research Expansion Act, which was signed into law by President Biden on Friday Dec. 2, 2022. The legislation establishes a new registration process for conducting research on marijuana and for manufacturing marijuana products for research purposes and drug development. “The study and development of cannabis for its potential therapeutic benefits…

Wednesday Dec 07, 2022 - 10:02 am

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Presents CYB003 Preclinical Data Amongst Leading Scientists, Academics in Neuropsychopharmacology

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), announced that it presented two posters on its deuterated psilocybin analog, CYB003, at the American College of Neuropsychopharmacology (“ACNP”) annual meeting taking place Dec. 4-7, 2022, in Phoenix, Arizona. According to the update, the data, including new pharmacokinetics (“PK”) findings, further strengthen the therapeutic profile of CYB003 as a novel…

Tuesday Dec 06, 2022 - 12:28 pm

InvestorNewsBreaks – MetAlert Inc. (MLRT) Engages IBN for Corporate Communications Expertise

MetAlert (OTC: MLRT), a pioneer in location-sensitive health monitoring devices and wearable technology products, today announced its selection of the corporate communications expertise of IBN, a multifaceted financial news and publishing company for private and public entities. With over 20 years of experience and an extensive portfolio of 30+ patents, MetAlert is a leading provider of innovative technology solutions to consumers/patients afflicted with Alzheimer’s, dementia…

Tuesday Dec 06, 2022 - 10:29 am

InvestorNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Names Experienced Researcher as Advisory Board Member

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotech company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, has appointed a new scientific advisory board member: Dr. Matthias Dobbelstein, director of the Institute of Molecular Oncology at the University Medical Center Göttingen in Germany since 2005 and also an associate member of the Max Planck Institute for Multidisciplinary…

Monday Dec 05, 2022 - 10:39 am

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Participate in ‘Ask the CEO’ Event

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that its Chief Executive Officer John Climaco will participate in the Virtual Investor “Ask the CEO” event. The live, moderated event is intended to provide the investment community direct access to ask their questions to Climaco on…

Friday Dec 02, 2022 - 1:19 pm

InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Recognized for ‘Unique Approach to Heart Attack Diagnosis’

HeartBeam (NASDAQ: BEAT) was recently named the winner of the annual Cardiovascular Innovations (“CVI”) 2022 Information Summit and Shark Tank Competition, an annual conference that focuses on innovative health solutions for cardiology clinicians. Awards presented at the conference recognize state-of-the-art cardiac technologies. “The company, which has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, has made a mark for…

Friday Dec 02, 2022 - 9:40 am

InvestorNewsBreaks — MetAlert Inc. (MLRT) Engages Veteran Firm as Financial Advisor to Assist with Growth Strategy, Corporate Development Initiatives

MetAlert (OTC: MLRT), a pioneer in location-sensitive, health-monitoring devices and wearable technology products for remote patient monitoring, announced that Joseph Gunnar & Co. LLC will serve as the company’s financial advisor. According to the announcement, Joseph Gunnar will support the company as it communicates its growth strategy to the investment community; the firm will also provide advice on possible financing alternatives and acquisitions and will…

Friday Dec 02, 2022 - 9:35 am

InvestorNewsBreaks – India Globalization Capital Inc. (NYSE American: IGC) Commences Trial Evaluating IGC-AD1 for the Treatment of Alzheimer’s-Related Symptoms

India Globalization Capital (NYSE American: IGC) announced that it has begun “A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Trial of the Safety and Efficacy of IGC-AD1 on Agitation in Participants with Dementia due to Alzheimer’s Disease.” According to the announcement, the company has commenced the phase 2 study at two U.S. sites and plans to add between three to five additional sites in the United…

Thursday Dec 01, 2022 - 12:27 pm

InvestorNewsBreaks — MetAlert Inc. (MLRT) ‘Groundbreaking’ Tech for Senior Health Care Market Spotlighted in Recent Article

MetAlert (OTC: MLRT), a pioneer in the field of wearable GPS human and asset tracking and remote patient monitoring, is featured in a recent Market Herald article for its proprietary technologies, including RoomMate(TM). The article, which is titled “One Company Is Set to Pioneer Technologies for the Senior Health Care Market,” reports on RoomMate, MetAlert’s groundbreaking 3D fall detection and monitoring device. The 3D infrared…

Thursday Dec 01, 2022 - 9:51 am

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases Pricing for Public Offering

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, announced the pricing of a public offering. The offering is comprised of 1,889,764 shares of common stock (or prefunded warrants in lieu thereof) along with warrants to purchase up to 1,889,764 shares of common stock at a combined public…

Wednesday Nov 30, 2022 - 1:59 pm

InvestorNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Q3 2022 Financial Results, Corporate Updates

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotech company that focuses on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, is reporting on its third quarter, the period ending Sept. 30, 2022; the report also included key company updates. Highlights of the report included the strategic research collaboration between BiondVax, the Max Planck Institute for Multidisciplinary Sciences and the…

Tuesday Nov 29, 2022 - 3:28 pm

InvestorNewsBreaks – BioRestorative Therapies Inc. (NASDAQ: BRTX) to Participate at RHK Capital Disruptive Growth Conference

BioRestorative Therapies (NASDAQ: BRTX), a life sciences company focused on adult stem cell-based therapies, today announced that its CEO Lance Alstodt will be participating at the RHK Capital Disruptive Growth Conference. The event is slated to take place in New York City from Dec. 5-6, 2022, and feature leading C-suite executives and senior management of up to 30 growth-oriented and disruptive companies. Attendees will include…

Tuesday Nov 29, 2022 - 1:16 pm

InvestorNewsBreaks – MetAlert Inc. (MLRT), Sensio Group Partner to Distribute 3D Monitoring System – RoomMate(TM)

MetAlert (OTC: MLRT), a pioneer in location-sensitive health monitoring devices and wearable technology products for remote patient monitoring, today announced its entry into a letter of intent (“LOI”) with Norway-based Sensio Group to begin marketing and distributing RoomMate(TM). A 3D infrared monitoring system, RoomMate is a simple and effective solution for looking after patients without intruding on their personal space. The solution allows for a…

Tuesday Nov 29, 2022 - 11:47 am

InvestorNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Confirms Inhalation Concept of NanoAb as Therapy for COVID-19

BiondVax (NASDAQ: BVXV) is a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. The company today announced statistically significant (p<0.001) efficacy results in a preclinical in vivo proof-of-concept study of its innovative inhaled nanosized antibody (“NanoAb”) COVID-19 therapy. “We are excited that the study results confirm the inhalation concept of our exclusively licensed…

Tuesday Nov 29, 2022 - 9:52 am

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) 1-for-30 Reverse Stock Split Now in Place

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has announced a 1-for-30 reverse split of its common stock. According to the announcement, the split was effective at 4:01 p.m. ET on Nov. 28, 2022. Starting today, CNSP common stock will trade on the Nasdaq Capital Market on a split-adjusted…

Wednesday Nov 23, 2022 - 2:55 pm

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Seeking to Solve Unmet Need for GBM Treatment

CNS Pharmaceuticals (NASDAQ: CNSP) is an oncology drug development company specializing in developing anti-cancer drugs for the treatment of primary and metastatic brain and central nervous system cancer. “The first half of fiscal 2022 saw the company make a number of clinical and operational advancements in its pursuit of treatment for Glioblastoma Multiforme (‘GBM’), according to CNS Pharmaceuticals CEO John Climaco. The company’s focus and…

Wednesday Nov 23, 2022 - 10:52 am

InvestorNewsBreaks – Odyssey Health Inc. (ODYY) Reports on Concussion Drug Progress, Provides Corporate Update

Odyssey Health (OTC: ODYY), formerly Odyssey Group International and a medical technology company focused on developing unique, life-saving medical products, has released an update on its concussion drug-development program. According to the release, in March 2022 the company acquired key intellectual property (“IP”) to a concussion drug, along with all rights to that drug. During the past few months, the company has completed strategic steps…

Tuesday Nov 22, 2022 - 9:50 am

InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Close on $6M Private Placement Funding

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, has closed on a private placement with two healthcare-focused institutional investors. The placement included the sale of 1,818,185 INM common shares, which were issued at a purchase price of $3.30 per share (or prefunded warrant in lieu thereof); the shares were priced at-the-market under NASDAQ rules.…

Monday Nov 21, 2022 - 11:05 am

InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Advancing Research of SPU-21 in Human Synovial Tissue

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced its plans to initiate a pilot study of its novel joint homing peptides targeting rheumatoid arthritis (“RA”), designated as SPU-21, in human synovial tissue surrounding joints and tendons. The three-month study will assess the binding affinity of the peptide in healthy human and RA synovial tissue,…

Monday Nov 21, 2022 - 10:01 am

InvestorNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) to Present at the January 2023 Biotech Showcase

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today announced that its CEO Amir Reichman will present at the upcoming Biotech Showcase conference. The event is slated to take place Jan. 9-11, 2023, in San Francisco in parallel to the J.P. Morgan (“JPM”) 41st Annual Health Care Conference. Reichman…

Friday Nov 18, 2022 - 10:31 am

InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Anticipated $6M Private Placement Funding

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, has entered into a securities purchase agreement with two healthcare-focused institutional investors. The agreement outlines plans for the issuance and sale of 1,818,185 of INM common shares; the shares will be issued at a purchase price of $3.30 per share or prefunded warrant. In addition, the…

Thursday Nov 17, 2022 - 10:18 am

InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Accounting VP, Controller

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, has named Sarah Li as vice president of accounting and InMed controller; the change will be effective Nov. 20, 2022. Li is replacing Brenda Edwards, who has been serving as interim chief financial officer for the company. Edwards joined InMed in the interim contract role in…

Wednesday Nov 16, 2022 - 1:04 pm

InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Expands Growing Portfolio with Valuable New Patent

HeartBeam (NASDAQ: BEAT), a cardiac technology company, has developed the first and only 3D-vector electrocardiogram (“VECG”) platform for timely heart attack detection. The company today announced that the United States Patent and Trademark Office has allowed its patent for a 12-lead electrocardiogram (“ECG”) smartwatch-based monitor intended for detection of heart attacks and complex cardiac arrhythmias. The innovation expands HeartBeam’s growing intellectual property portfolio enabling 12-lead…

Wednesday Nov 16, 2022 - 10:57 am

InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Gains Alliance Grant Funding, Launches New Program with UBC Professor

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, has unveiled a new neurodegenerative disease program (“INM-900 series”). The program will focus on studying the effects of cannabinoid analogs in neurodegenerative diseases such as Alzheimer’s, Huntington’s and Parkinson’s. Prior to this announcement, InMed had identified potential cannabinoid analogs that exhibited promising effects particularly in relation…

Tuesday Nov 15, 2022 - 12:31 pm

InvestorNewsBreaks – Odyssey Health Inc. (ODYY) Announces Upcoming Annual Meeting of Stockholders

Odyssey Health (OTC: ODYY), formerly Odyssey Group International and a medical technology company focused on developing unique, life-saving medical products, has scheduled its Annual Meeting of Stockholders; the meeting is slated for Jan. 12, 2023. According to the announcement, any proposals to be considered for the meeting should be sent to the company’s principal executive offices in Las Vegas; all proposals must comply with the…

Tuesday Nov 15, 2022 - 12:13 pm

InvestorNewsBreaks – QSAM Biosciences Inc. (QSAM) Announces Q3 2022 Results, Provides Corporate Update

QSAM Biosciences (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam(R)), for the treatment of bone cancer and related diseases, today announced financial results for the third quarter ended Sept. 30, 2022, and provided a corporate update. “Initial, preliminary data from our second patient dosed with CycloSam continues to show positive signals in terms of safety and efficacy. While it is too early…

Tuesday Nov 15, 2022 - 11:04 am

InvestorNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Congratulates Dirk Görlich on $1.4M World Laureates Association Prize in Life Sciences

BiondVax (NASDAQ: BVXV) is a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. The company today congratulated its co-lead scientific research collaborator Professor Dr. Dirk Görlich, director at the Max Planck Institute for Multidisciplinary Sciences (“MPI”), on being awarded the inaugural $1.4 million World Laureates Association (“WLA”) Prize in Life Sciences or Medicine…

Tuesday Nov 15, 2022 - 10:47 am

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Q2 Results, Recent Business Highlights, Presentation of CYB003 Preclinical Data at Neuroscience 2022

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), has reported unaudited financial results for its second quarter ended Sept. 30, 2022, as well as recent business highlights. “We have continued to make progress as planned, advancing our clinical pipeline of modified psychedelic-based molecules while also strengthening our drug discovery platform of differentiated preclinical compounds,” said Cybin’s CEO Doug…

Monday Nov 14, 2022 - 3:02 pm

InvestorNewsBreaks – Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) Announces Strategic Move to Sell Alta Mesa Project, Focus on Uranium and Rare Earth Production

Energy Fuels (NYSE American: UUUU) (TSX: EFR), a leading U.S. producer of uranium and rare earth elements (“REE”), today announced its entry into a definitive agreement to sell three wholly owned subsidiaries that together hold its Alta Mesa ISR Project to enCore Energy for total consideration of $120 million (the “transaction”). The transaction, which is expected to close by the end of 2022 or early…

Monday Nov 14, 2022 - 9:53 am

InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Q1 2023 Financial Report, Corporate Update

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing and clinical development of rare cannabinoids, has reported its financial results for the first quarter of fiscal year 2023, ended Sept. 30, 2022. Highlights of the report included updates on the company’s pharmaceutical development programs, including INM-755 for the treatment of epidermolysis bullosa (“EB”) and INM-088 for the treatment of glaucoma. According to the report, enrollment and…

Friday Nov 11, 2022 - 10:04 am

InvestorNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Releases Q3 2022 Financial Report

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (“VECG”) platform for heart attack detection anytime, anywhere, is reporting its financial and operational updates for the third quarter; the quarter ended on Sept. 30, 2022. Included in the report is the fact that the company’s AIMI(TM) platform technology, which is used for diagnosing heart attacks, has been submitted…

Thursday Nov 10, 2022 - 12:13 pm

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Progress on Clinical Path for CYB004

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), today announced progress on its CYB004-E Phase 1 trial evaluating N,N-dimethyltryptamine (“DMT”). According to the update, dosing has been completed for four out of five participant cohorts, and The Safety Review Committee has confirmed no clinically significant safety or tolerability issues. The trial was acquired from Entheon Biomedical Corp. in…

InvestorNewsBreaks

NewsBreak Category: Biotechnology

Get Started with InvestorWire

Press Distribution

Explore Press Distribution Solutions

Discover Add-on Solutions